QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Among prostate cancer patients, higher pre-operation PSA levels and higher Gleason scores are often associated with a poorer prognosis after radical prostatectomy. However, some prostate cancer tumors actually secrete less PSA than other tumors and in these patients, PSA levels…
President Barack Obama recently solicited a Prostate Specific Antigen test to screen for prostate cancer during his yearly physical. White House physician Dr. Jeffrey C. Kuhlman’s report, which was released October 31, said the test was performed after the President…
An accumulating body of increasingly compelling evidence shows that PSA screening can reduce prostate cancer (CaP) deaths and is changing the way clinicians view prostate cancer screening. When you think about it, there would be no point in trying to…
Last May, I was invited by the American Urological Association to give the Ramon Guiteras Lecture. This opportunity was an honor for me, as I was selected by my own professional association to give this lecture to the membership. …
The need for repeat prostate biopsies is a common occurrence in men with elevated PSA levels or a suspicious digital examination whose initial biopsies do not show prostate cancer. Dr. Catalona suggested that with the recent ability to perform a…
This article is a follow-up to the article in the Winter 2010 QUEST which introduced the research on Nanotechnology to help make better treatment decisions after a radical prostatectomy. The Nanotechnology PSA test described in this material is not commercially…
(This article is prepared for QUEST readers from a study published in the Journal of Clinical Oncology and introduces readers to a vocabulary important for interpreting recent numbers on prostate cancer screening and prostate cancer mortality.) “If you don’t do…
This article is based upon a study* supported in part by the URF and presented at a recent American Urological Association meeting. PSA is the long-standing and accepted method for early detection of prostate cancer and for recommendation of biopsies;…
In December, 2010 an FDA advisory panel met to evaluate two proposals for the use of 5a reductase inhibitors to reduce the risk of prostate cancer. The panel rejected both voting 17-0 with one abstention that the risks of Proscar…
The two companies presented results of clinical trials claiming the drugs reduce the risk of prostate cancer. However, in both studies, men who took these drugs for several years had a higher rate of the potentially lethal high-grade prostate cancers….
"*" indicates required fields
